CG Oncology spent $54.7 million on research and development in three months, roughly 46 times its $1.2 million of revenue. The company has crossed the line from zero sales, but its clinical-development bill is operating on an entirely different scale.
That showed up in the bottom line. Net loss widened to $79.1 million from $41.4 million a year earlier, while operating loss reached $86.4 million from $48.7 million. Revenue was zero in the comparable period, so the new sales line is meaningful, just not yet large enough to absorb the work behind it.
Management points to a specific source for the increase. The company said R&D rose by $23.3 million, with most of that increase tied to external clinical-trial expenses.
"The increase of $23.3 million in R&D expenses for the three months ended June 30, 2026 was primarily due to an increase of $21.3 million in external clinical trial expenses related to higher Chemistry, Manufacturing, and Controls (CMC) costs, as well as an increase of $2.7 million in compensation costs due to increased headcount, including a $0.8 million increase in stock-based compensation, partially offset by a decrease in other research and development costs of $0.6 million."
CG Oncology, 10-Q, Aug. 6, 2026
In plain English, the larger loss was chiefly a development-cost story, not a revenue shortfall against some disclosed target. CMC covers the chemistry, manufacturing, and controls work needed to support a clinical program, and the filing identifies that work as the main incremental expense.
The company also gives the broader stage-of-development explanation:
"Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials."
CG Oncology, 10-Q, Aug. 6, 2026
That makes the filing harder to reduce to either “commercial launch” or “cash-burning biotech.” Both descriptions fit part of the page. CG Oncology had $19.6 million in cash at June 30, up from $14.6 million a year earlier, but the supplied filing receipts do not identify what drove that increase. Diluted shares rose to 88.2 million from 76.2 million, another change sitting alongside the larger research bill.
The company’s annual results show that revenue has been building, from $204.0K in 2023 to $4.0M in 2025. The latest three-month filing marks another step in that direction, while also showing how far sales remain from the expense base required by the pipeline. At the latest close, CG Oncology’s market capitalization was $5.6B, and the company’s enterprise value to sales ratio was 1376.6x based on the latest annual facts. Those figures describe the scale of the valuation relative to current sales, not a forecast of future results.
CG Oncology’s next quarterly report will provide the next comparable read on external clinical-trial spending, especially the CMC component, alongside revenue and cash. The unresolved tension is simple: revenue has started, but the clinical cost base is still vastly larger.